The current stock price of TMCI is 2.26 USD. In the past month the price decreased by -9.6%. In the past year, price decreased by -77.95%.
ChartMill assigns a fundamental rating of 3 / 10 to TMCI. TMCI may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months TMCI reported a non-GAAP Earnings per Share(EPS) of -0.8. The EPS increased by 14.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.49% | ||
| ROE | -56.18% | ||
| Debt/Equity | 0.62 |
11 analysts have analysed TMCI and the average price target is 4.93 USD. This implies a price increase of 118.33% is expected in the next year compared to the current price of 2.26.
For the next year, analysts expect an EPS growth of 4.7% and a revenue growth 2.04% for TMCI
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 21.24 | 190.25B | ||
| ISRG | INTUITIVE SURGICAL INC | 55.62 | 176.09B | ||
| SYK | STRYKER CORP | 27.01 | 140.78B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.14 | 136.19B | ||
| BDX | BECTON DICKINSON AND CO | 14 | 57.63B | ||
| IDXX | IDEXX LABORATORIES INC | 48.94 | 51.07B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.16 | 47.96B | ||
| RMD | RESMED INC | 24.78 | 37.18B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.45 | 36.49B | ||
| DXCM | DEXCOM INC | 38.99 | 28.29B | ||
| PODD | INSULET CORP | 56.15 | 18.05B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.66 | 17.09B |
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
TREACE MEDICAL CONCEPTS INC
100 Palmetto Park Place
Ponte Vedra FLORIDA 32081 US
CEO: John T. Treace
Employees: 477
Phone: 19043735940
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 477 full-time employees. The company went IPO on 2021-04-23. The company is advancing the standard of care for the surgical management of bunion and related midfoot deformities. The company has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. The company has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. The company sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
The current stock price of TMCI is 2.26 USD. The price decreased by -2.59% in the last trading session.
TMCI does not pay a dividend.
TMCI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
TREACE MEDICAL CONCEPTS INC (TMCI) has a market capitalization of 144.01M USD. This makes TMCI a Micro Cap stock.
You can find the ownership structure of TREACE MEDICAL CONCEPTS INC (TMCI) on the Ownership tab.